AstraZeneca Xigduo XR Has Been Approved By China's National Medical Products Administration For Adults With Type-2 Diabetes As An Adjunct To Diet And Exercise To Improve Glycemic Control
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's Xigduo XR has received approval from China's National Medical Products Administration for use in adults with type-2 diabetes as an adjunct to diet and exercise to improve glycemic control.
June 27, 2023 | 8:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Xigduo XR has been approved in China for type-2 diabetes treatment, potentially increasing the company's market share in the diabetes sector.
The approval of Xigduo XR in China will allow AstraZeneca to tap into the growing diabetes market in the country. This could lead to increased sales and revenue for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100